-
Bayer poachs another GSK executive to lead its strategic oncology business unit
Time of Update: 2022-05-30
At Bayer, Roth and Frenkl will focus on developing the prostate cancer drug Nubeqa .
-
Bayer withdraws PI3K inhibitor application for one indication
Time of Update: 2022-05-28
Bayer submitted the first domestic application for the product in March 2021 for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two systemic therapies in the past.
-
Bayer's Kerendia gets EU approval to compete with AZ and Eli Lilly's SGLT-2 inhibitors
Time of Update: 2022-05-28
Compilenewborn>Recently, Bayer's new kidney disease drug Kerendia (finerenone, feneridone, 10mg or 20mg) was approved in the European Union, the drug
-
Bayer's TRK inhibitor larotrectinib approved in China
Time of Update: 2022-05-22
Today, the NMPA official website announced that the marketing application for larotrectinib (larotrectinib sulfate capsules) submitted by Bayer has been approved for the treatment of adult and pediatric patients with solid tumors carrying the NTRK fusion gene .
-
Chia Tai Tianqing enters Bayer's 1 billion contrast agent and competes with Chengdu Bite for the first imitation
Time of Update: 2022-05-15
Figure 1: The latest product status of Chia Tai Tianqing Pharmaceutical Group Source: CDE official website Figure 2: Bayer's sales of iopromide (unit: 100 million yuan) Source: Minet.
-
Bayer's new ingredient fluoxapiprolin and formulation product Xivana Prime will be approved in Australia!
Time of Update: 2022-05-11
Australian Pesticide Veterinary Drug Administration Fungicides Fluoxapiprolin is a novel piperidinethiazole isoxazoline fungicide, which adopts the oxidative sterol binding protein inhibitor mode of action and is active against many oomycete fungi .
-
Bayer's Nubeqa Receives FDA Priority Review for the Treatment of mHSPC
Time of Update: 2022-05-09
Based on positive data from the Phase 3 ARASENS trial, Bayer raised Nubeqa's peak annual sales, which it expects to reach 3 billion euros .
-
FDA grants Bayer's oral FXIa inhibitor asundexian Fast Track designation!
Time of Update: 2022-05-03
asundexian is an oral factor XIa (FXIa) inhibitor currently being developed as a potential drug for secondary prevention in patients with NCIS, as well as 2 other diseases: atrial fibrillation (irregular heartbeat) and recent myocardial infarction (heart attack) .
-
Courier Significantly Extends Lives in Selected Prostate Cancer Patients, Bayer's Innovative Combination Therapy Filed in Japan
Time of Update: 2022-05-01
England Journal of Medicine . The trial randomized 1306 newly diagnosed patients in a 1:1 ratio to receive 600 mg of dalotamide twice daily or placebo, plus ADT and docetaxel
-
Bayer files for expansion of Nubeqa indication in US and EU
Time of Update: 2022-04-29
The filing is based on data from the ARASENS Phase 3 trial showing a statistically significant improvement in overall survival with Nubeqa combined with androgen deprivation therapy (ADT) and chemotherapy docetaxel in men with metastatic hormone-sensitive prostate cancer .
-
Novartis' PSMA targeted therapy has been approved, and Bayer, Amgen, etc. are all under development. What is the development prospect of PSMA?
Time of Update: 2022-04-29
Combining PSMA-targeted radioligand therapy with immune checkpoint inhibitors to achieve synergistic anti-cancer effects in different types of antibodies Bispecific T-cell adaptor proteins (BiTEs) are a class of bispecific antibodies that have received much attention in recent years.
-
Bayer's innovative combination therapy submits application for additional indications in Japan
Time of Update: 2022-04-29
to receive 600 mg of dalotamide twice daily or placebo, plus ADT and docetaxel . The results of the trial showed that in men with mHSPC, the combination of dalotamide + ADT + docetaxel showed
-
Bayer Submits Indication Expansion Application for Feneridone in Patients with Early-Stage Chronic Kidney Disease and Type 2 Diabetes in the EU
Time of Update: 2022-04-28
with early-stage chronic kidney disease and type 2 diabetes . The filing is based on positive data from the FIGARO-DKD study, which showed that feneridone
-
Bayer sells pest control business for 2.4 billion euros
Time of Update: 2022-04-24
Bayer's Pest Control business provides environmental solutions for the control of pests and weeds in non-agricultural sectors such as vector control, professional pest management, vegetation management, forestry, turf and ornamental plants .
-
Bayer's new corn herbicide TriVolt (thianosulfuron + flufenacet + isoxaflutole) has been registered in the United States
Time of Update: 2022-04-16
TriVolt is a new selective corn herbicide from Bayer that provides corn growers with built-in resistance management and sustained high levels of weed control .
-
Bayer's Factor XIa Inhibitor Stroke Clinical Program Receives U.S. FDA Fast Track Designation
Time of Update: 2022-03-04
XIa Asundexian a sundexianFast Track designation is designed to facilitate the accelerated development of drug candidates for serious diseases to address unmet medical needs, with the goal of bringing important new treatments to patients earlier .
-
Bayer launches upgraded grain fungicide Prosaro® PRO (Prothioconazole + Tebuconazole + Fluopyram) in the United States
Time of Update: 2022-03-03
prothioconazole tebuconazole "The fungicide Prosaro PRO is another innovative solution for grain growers to protect their crops from foliar and crown diseases," said Lindsey Aagesen, U.
-
Bayer restarts plan to introduce new GM cotton seeds in India
Time of Update: 2022-03-02
Germany 's Bayer has applied to plant its next-generation genetically modified (GM) cotton seeds in India , government sources said, reviving plans to bring high-yielding, herbicide -tolerant varieties into the country .
-
Former Bayer executive appointed as CEO of China National Bluestar Co., Ltd.
Time of Update: 2022-03-02
Koenig's experience in the above-mentioned fields and global business management will not only enable him to quickly integrate into the Bluestar system and culture, but it is also expected to help Bluestar achieve global expansion in multiple areas .
-
Monsanto rejects Bayer's $62 billion acquisition
Time of Update: 2022-02-26
Bayer of Germany issued a statement on the 23rd, proposing to acquire Monsanto for US$62 billion at a price of US$122 per share .
